Association between serum ficolin-1 level and disease progression in primary biliary cholangitis

Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.

INTRODUCTION Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be associated with CCA in a Japanese cohort of PSC patients. Our aim in this study ...

Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia

OBJECTIVE The etiopathogenesis and risk for development of biliary neoplasia in primary sclerosing cholangitis (PSC) are largely unknown. Microbes or their metabolites have been suggested to play a role. To explore this potential microbial involvement, we evaluated the differences in biliary microbiota in PSC patients at an early disease stage without previous endoscopic retrograde cholangiogra...

Primary sclerosing cholangitis and primary biliary cirrhosis.

Preview Although primary sclerosing cholangitis occurs most often in middle-aged or younger men and primary biliary cirrhosis in middle-aged or older women, the diseases have some traits in common-unfortunate ones. In both diseases, the cause is unknown, and liver transplantation is the only known effective therapy for advanced cases. Dr Fennerty discusses trials of medical treatments used in a...

Concurrence of multiple sclerosis and primary biliary cholangitis: A case series study

Obeticholic Acid in Primary Biliary Cholangitis.

In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo. Pruritus (and serious adverse effects) was observed more frequentl...